15 Years Closer to a Cure for Neuroendocrine Cancer

Since 2005, NETRF has invested more than $30 million in the search for a cure for neuroendocrine cancer. We are proud of the impact we’ve made on research and the NETRF-funded breakthroughs that are advancing the understanding and treatment of neuroendocrine cancer. NETRF is leading private funder in NET research. To date, we’ve funded more than 90 studies on four continents. Those studies have resulted in the publication of more than 150 scientific papers and 5,050 citations. To learn more about the science we are making possible, visit our research portfolio. (RESEARCH PORTFOLIO)

Celebrating the People Who Make Our Mission Possible

In honor of our 15th Anniversary, we’d like to introduce you to a few members of our remarkable community. Since our founding, NETRF has received more than 25,000 gifts. This incredible outpouring of support and generosity has made it possible for us to transform and advance the field of NET research. We know there is more work to be done and we promise to keep building on the scientific momentum we have achieved. There are so many people who give their time, talent and treasure to NETRF … these are just a few of their stories. If you have a story to share about why you support NETRF, we’d love to hear from you. Please reach out to Susan.Payson@netrf.org to participate in this milestone celebration. (LEARN MORE)

NETRF-Funded Research Results in First Molecular Map of Lung Neuroendocrine Neoplasms

In 2019, NETRF awarded Lynette Fernandez-Cuesta, PhD, of the International Agency for Research on Cancer in Lyon, France with an Investigator Award to study the molecular underpinnings of lung supra-carcinoids, an aggressive subtype of NETs. To date, there is no explanation of why some tumors grow slowly, and others very aggressively. By understanding the characteristics of lung supra-carcinoids and developing lab models that mimic the growth of supra-carcinoids, Fernandez-Cuesta hopes to identify potential drug targets for treating the disease, identify better screening and treatment approaches and develop molecular profiling data to inform future research on how supra-carcinoids develop and grow.

“While only a year has passed since we obtained the NETRF Investigator Award, our research has already produced the first molecular map of lung neuroendocrine neoplasms,” says Fernandez-Cuesta. “It’s an interactive tool that allows for integration of transcriptomic data from different studies to accelerate discoveries on these rare cancers.”
Fernandez-Cuesta’s work was recently published in the scientific journal GigaScience. To learn more about Cuesta-Fernandez’s NETRF-funded research to identify what opportunities exist to interrupt the cellular pathways to stop or slow the tumor growth of lung supra-carcinoids, visit our website. (LEARN MORE)

NETRF-Funded Researcher Receives Prestigious International Award

Hans Clevers, MD, PhD, is regarded as one of the world’s leading experts in 3D cancer cell models. He’s responsible for a series of breakthrough discoveries that led to the development of mini-organs grown in Petri dishes. These miniature human organs, now called organoids, are used as laboratory models to study the causes and treatment of cancers and are considered an “essential first step toward the growth of the regenerative cancer medicine field.” The American Association for Cancer Research recently presented Dr. Clevers with the 2021 Pezcoller Foundation International Award for Extraordinary Achievement in Cancer Research.

In 2017, NETRF awarded Dr. Clevers with a four-year Petersen Accelerator Award to develop NET organoids from lung, intestine and pancreas tumor tissues. Dr. Clevers and his team at the Hubrecht Institute, Netherlands have made extraordinary progress in their efforts to grow human organoids from tumor tissues derived from metastatic NETs. To date, the Clevers' lab has generated more than 50 NET organoid lines. NETRF congratulates Dr. Clevers on this prestigious award and thanks him for his remarkable contribution to NET cancer research. (LEARN MORE)

Which NET Treatments Should I Have and in What Order?

If you’ve asked this question about your NET treatments and procedures, you are not alone. Currently, there are no clear guidelines regarding the optimum sequencing of NET therapeutic options. A researcher at the University of Iowa College of Public Health aims to change that. Dr. Michael O’Rorke, an assistant professor of epidemiology, was recently awarded a $5 million grant to lead a three-year study to help determine which care options work, for whom and under which circumstances. (CONTINUE READING)

Physicians have stepped up in unprecedented ways to care for the NET community since the start of the COVID-19 pandemic. It is now more important than ever to ensure they feel gratitude for their hard work and dedication. NETRF is dedicating the month of April to all NET health care providers. Please join us in showing our appreciation to as many doctors, nurses and NET specialists as we can. If you are able, please make a gift to NETRF before May 3, in honor of your NET specialist. Say thank you and NETRF will send a Certificate of Applause along with your message of appreciation to your NET care provider.

What You Need to Know About NETs

We know that many of you are new to your NET diagnosis and you likely have a lot of questions. We’d like to take a moment to give you an introduction to NETs and what you need to know about them. That means taking you to the beginning of our Podcast series NETWise. In Episode 1, we provide an understanding of the basics of neuroendocrine tumor diagnosis. Join us as we take a deep dive into understanding prognosis, defining stage and grade of NETs and the “upside down” nature of NET primaries and metastases. Plus, we have episode infographics that you can download to help provide you with a better visual understanding as you listen to the podcast. (LISTEN NOW) 

Test Your Knowledge of NET Genetics with NETQuiz #18

Do you know what role genetics play in neuroendocrine tumors? Could you or your loved ones’ benefit from genetic screening? In our most recent episode of NETWise, we talk with leading NET specialists from around the country about the relationship between NETs and DNA. Listen now and learn how your genetic code could hold important implications for treatment strategies, prognosis, and the health of your family members. Then take the LACNETS quiz to test your knowledge of NET genetics. (TAKE QUIZ)

Improving Global Access to NET Treatments and Care

NETRF, a member of the International Neuroendocrine Cancer Alliance (INCA), is pleased to collaborate with the International Neuroendocrine Cancer Alliance (INCA) to share the results from INCA’s Survey of Challenges in Access to Diagnostics and Treatments for NET patients (SCAN). The SCAN is the most significant global compendium of data about neuroendocrine tumors (NETs) created to date. The hope is that this data will be used by health care professionals, patients and researchers around the world to advance NET care and treatments. The SCAN was conducted in 2019, with participation from more than 2,359 patients and 436 health care providers. (LEARN MORE)

Do You Need Health Insurance?

The federal government and many states are offering a special three-month enrollment period in response to the COVID-19 public health emergency. Between now through August 15, 2021, you can enroll in coverage, change plans or see if you qualify for Medicaid. If you are already enrolled in Marketplace coverage, you may also qualify for more increased financial support made possible by the American Rescue Plan Act of 2021. (LEARN MORE)




Doctor Database   Patient Groups
Newly Diagnosed   About NETs
Facebook Twitter
Contact Us

NET Research Foundation
31 St. James Avenue, Suite 365
Boston, MA 02116

(617) 946-1780 | info@netrf.org
The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.
powered by emma
Subscribe to our email list.